# A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

> **NCT03144674** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 110 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Parsaclisib

## Key facts

- **NCT ID:** NCT03144674
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2021-01-15
- **Final completion:** 2024-05-29
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144674, "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03144674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*